Literature DB >> 23305783

Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments.

Moritz Haneklaus1, Luke A J O'Neill, Rebecca C Coll.   

Abstract

The protein NLRP3 has emerged as a central regulator in the inflammatory process, being implicated directly in hereditary cryopyrinopathies, and indirectly in diseases such as gout, Type 2 diabetes and atherosclerosis. NLRP3 is an important regulator of caspase-1, the enzyme that processes the immature form of IL-1β into the active protein. The control of NLRP3 has therefore become a focus of research with evidence for redox regulation, ubiquitination and regulation by miRNA-223, kinases and calcium all emerging as controllers of NLRP3. As our knowledge expands the prospect for precise pharmacological targeting of NLRP3 will improve and could lead to substantial clinical utility.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23305783     DOI: 10.1016/j.coi.2012.12.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  74 in total

1.  AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages.

Authors:  Yun Wang; Benoit Viollet; Robert Terkeltaub; Ru Liu-Bryan
Journal:  Ann Rheum Dis       Date:  2014-10-31       Impact factor: 19.103

Review 2.  Is immunity a mechanism contributing to statin-induced diabetes?

Authors:  Brandyn D Henriksbo; Jonathan D Schertzer
Journal:  Adipocyte       Date:  2015-04-20       Impact factor: 4.534

3.  Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats.

Authors:  Li-hong Ding; Dan Liu; Min Xu; Hong Liu; Min Wu; Ri-ning Tang; Lin-li Lv; Kun-ling Ma; Bi-cheng Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

Review 4.  Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.

Authors:  Gina A Montealegre Sanchez; Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Rheum Dis Clin North Am       Date:  2013-09-21       Impact factor: 2.670

Review 5.  The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.

Authors:  Eleni Pitsillou; Sarah M Bresnehan; Evan A Kagarakis; Stevano J Wijoyo; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

Review 6.  Melatonin, clock genes and mitochondria in sepsis.

Authors:  Darío Acuña-Castroviejo; Ibtissem Rahim; Carlos Acuña-Fernández; Marisol Fernández-Ortiz; Jorge Solera-Marín; Ramy K A Sayed; María E Díaz-Casado; Iryna Rusanova; Luis C López; Germaine Escames
Journal:  Cell Mol Life Sci       Date:  2017-08-07       Impact factor: 9.261

Review 7.  Adaptation in the innate immune system and heterologous innate immunity.

Authors:  Stefan F Martin
Journal:  Cell Mol Life Sci       Date:  2014-07-06       Impact factor: 9.261

8.  RNA-seq methods for identifying differentially expressed gene in human pancreatic islet cells treated with pro-inflammatory cytokines.

Authors:  Bo Li; Chang Long Bi; Ning Lang; Yu Ze Li; Chao Xu; Ying Qi Zhang; Ai Xia Zhai; Zhi Feng Cheng
Journal:  Mol Biol Rep       Date:  2014-03-12       Impact factor: 2.316

9.  The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity.

Authors:  Sangjun Park; Christine Juliana; Sujeong Hong; Pinaki Datta; Inhwa Hwang; Teresa Fernandes-Alnemri; Je-Wook Yu; Emad S Alnemri
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

Review 10.  Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.

Authors:  Giacomo Emmi; Maria Letizia Urban; Massimo Imazio; Marco Gattorno; Silvia Maestroni; Giuseppe Lopalco; Luca Cantarini; Domenico Prisco; Antonio Brucato
Journal:  Curr Cardiol Rep       Date:  2018-06-14       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.